🇺🇸 FDA
Pipeline program

Mevac-A vaccine

PED-2566-0634

Phase 3 mab completed

Quick answer

Mevac-A vaccine for HAV is a Phase 3 program (mab) at Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., with 1 ClinicalTrials.gov record(s).

Program details

Company
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co.,
Indication
HAV
Phase
Phase 3
Modality
mab
Status
completed

Clinical trials